The Trump administration is turning to an unconventional approach to lowering drug prices in the United States: striking deals directly with Big Pharma companies in an attempt to bring U.S. prices in line with what other countries pay. Trump and the nation's healthcare officials have touted these 'most-favored nation' deals as the most effective means to getting pharmaceutical prices down, beyond even the power of the Medicare drug price negotiations already in place. The key issue, health experts say, is that the public has had little visibility into these deals.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
